

Special Issue

Cancer Vaccines: Current Advances, Clinical Applications, and Future Directions

Message from the Guest Editors

Anticancer vaccines represent another approach to tumor immunotherapy. Preventive vaccines, such as anti-HPV or -HBV, proved their efficacy in reducing the risk of cancer development. However, therapeutic vaccines aim to reshape one's immunological profile to increase cytotoxic and anticancer properties to treat an already present tumor. Introducing mRNA, DNA, neoantigens, or stimulated dendritic cells promotes the presentation of cancer antigens, thus enhancing CD8+ T cell-mediated anticancer effects. Implementing anticancer therapeutic vaccines should broaden the treatment potential in cancers with difficulties in developing targeted therapies. Furthermore, it could improve the anticancer activity of other oncological therapeutics or reduce treatment resistance. This Special Issue aims to present original research papers and reviews that provide updates and discuss novel opportunities for anticancer therapeutic vaccines. Manuscripts and reviews in the following research areas are encouraged: nucleic acid vaccines, cellular vaccines, viral vaccines, preclinical and clinical studies, and translational medicine.

Guest Editors

Dr. Paulina Niedźwiedzka-Rystwej

Dr. Kajetan Kielbowski

Dr. Rafał Becht

Deadline for manuscript submissions

28 February 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/234965

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).